Keros Therapeutics (NASDAQ:KROS) Reaches New 1-Year Low – What’s Next?

Keros Therapeutics, Inc. (NASDAQ:KROS)’s stock price hit a new 52-week low during mid-day trading on Thursday . The company traded as low as $18.49 and last traded at $18.49, with a volume of 1654192 shares changing hands. The stock had previously closed at $68.65.

Wall Street Analyst Weigh In

A number of research analysts have commented on KROS shares. Guggenheim reaffirmed a “buy” rating and set a $102.00 price target (up previously from $96.00) on shares of Keros Therapeutics in a research report on Wednesday, December 4th. Jefferies Financial Group initiated coverage on Keros Therapeutics in a report on Tuesday, November 5th. They set a “buy” rating for the company. Scotiabank cut their price target on shares of Keros Therapeutics from $77.00 to $44.00 and set a “sector outperform” rating on the stock in a report on Friday. Wedbush restated an “outperform” rating and issued a $84.00 price objective on shares of Keros Therapeutics in a report on Thursday, November 7th. Finally, Wells Fargo & Company lifted their target price on shares of Keros Therapeutics from $88.00 to $111.00 and gave the company an “overweight” rating in a research note on Wednesday. Three analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $85.67.

Keros Therapeutics Stock Performance

The business’s 50-day moving average is $59.11 and its 200-day moving average is $52.63. The company has a market capitalization of $762.75 million, a PE ratio of -3.61 and a beta of 1.20.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The business had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business’s revenue was up 4750.0% on a year-over-year basis. During the same period last year, the firm earned ($1.33) EPS. Analysts expect that Keros Therapeutics, Inc. will post -5.26 EPS for the current year.

Institutional Investors Weigh In On Keros Therapeutics

A number of institutional investors have recently modified their holdings of the stock. KBC Group NV raised its position in shares of Keros Therapeutics by 52.0% in the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after purchasing an additional 432 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Keros Therapeutics by 26.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after purchasing an additional 280 shares during the last quarter. Values First Advisors Inc. bought a new stake in Keros Therapeutics during the 3rd quarter valued at about $89,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Keros Therapeutics in the second quarter worth about $128,000. Finally, LMR Partners LLP bought a new position in shares of Keros Therapeutics in the third quarter worth approximately $213,000. 71.56% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.